Bicara Therapeutics (NASDAQ:BCAX) COO Ryan Cohlhepp Sells 28,214 Shares of Stock

Bicara Therapeutics Inc. (NASDAQ:BCAX) COO Ryan Cohlhepp sold 28,214 shares of the company’s stock in a transaction on Wednesday, July 8th. The stock was sold at an average price of $28.98, for a total value of $817,641.72. Following the sale, the chief operating officer owned 182,177 shares of the company’s stock, valued at $5,279,489.46. This trade represents a 13.41% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Ryan Cohlhepp also recently made the following trade(s):

• On Thursday, July 9th, Ryan Cohlhepp sold 536 shares of Bicara Therapeutics stock. The shares were sold at an average price of $29.00, for a total value of $15,544.00.
• On Friday, May 15th, Ryan Cohlhepp sold 12,500 shares of Bicara Therapeutics stock. The stock was sold at an average price of $20.29, for a total transaction of $253,625.00.
• On Wednesday, April 15th, Ryan Cohlhepp sold 12,500 shares of Bicara Therapeutics stock. The shares were sold at an average price of $23.01, for a total transaction of $287,625.00.

Bicara Therapeutics Price Performance

Shares of BCAX stock traded down $0.77 during mid-day trading on Friday, hitting $28.91. 584,437 shares of the stock traded hands, compared to its average volume of 1,011,479. Bicara Therapeutics Inc. has a 52-week low of $9.47 and a 52-week high of $30.99. The stock has a market cap of $1.90 billion, a P/E ratio of -10.40 and a beta of -0.81. The stock’s fifty day moving average is $23.43 and its two-hundred day moving average is $20.10.

Bicara Therapeutics (NASDAQ:BCAX) last issued its quarterly earnings data on Monday, May 11th. The company reported ($0.93) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.72) by ($0.21). As a group, equities analysts forecast that Bicara Therapeutics Inc. will post -3.48 EPS for the current fiscal year.

Analyst Ratings Changes

Several brokerages have recently commented on BCAX. Morgan Stanley increased their price objective on Bicara Therapeutics from $36.00 to $37.00 and gave the company an “overweight” rating in a report on Tuesday, May 12th. The Goldman Sachs Group boosted their target price on Bicara Therapeutics from $16.00 to $18.00 and gave the stock a “neutral” rating in a research note on Tuesday, May 12th. Wells Fargo & Company increased their price target on Bicara Therapeutics from $11.00 to $16.00 and gave the company an “equal weight” rating in a research note on Tuesday, March 31st. Wedbush reissued an “outperform” rating and issued a $30.00 price target on shares of Bicara Therapeutics in a report on Tuesday, March 31st. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Bicara Therapeutics in a research note on Wednesday, May 27th. One analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $30.27.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of BCAX. T. Rowe Price Investment Management Inc. boosted its position in Bicara Therapeutics by 596.5% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 3,236,595 shares of the company’s stock valued at $54,472,000 after buying an additional 2,771,868 shares during the last quarter. Janus Henderson Group PLC purchased a new position in Bicara Therapeutics during the 4th quarter worth approximately $44,484,000. Vestal Point Capital LP raised its position in Bicara Therapeutics by 80.6% during the 2nd quarter. Vestal Point Capital LP now owns 5,000,000 shares of the company’s stock worth $46,450,000 after buying an additional 2,231,025 shares during the last quarter. Franklin Resources Inc. acquired a new stake in Bicara Therapeutics during the 4th quarter valued at approximately $27,265,000. Finally, State Street Corp lifted its stake in Bicara Therapeutics by 179.5% during the 4th quarter. State Street Corp now owns 1,649,537 shares of the company’s stock valued at $27,762,000 after acquiring an additional 1,059,260 shares during the period.

Bicara Therapeutics Company Profile

Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company’s research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.

The company’s lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.